Stripe commits $500 million to Intercept nonprofit to eliminate respiratory viruses, with Anthropic and OpenAI Foundation as co-backers

Stripe announced on June 24, 2026 that it will commit $500 million to launch Intercept, a new nonprofit dedicated to ending respiratory infections — starting with the common cold and flu, and ultimately aiming to eliminate respiratory viruses entirely. Anthropic and the OpenAI Foundation are among its founding backers.

What's new

Stripe is the lead funder, pledging $500 million to establish and capitalize Intercept. The additional founding backers include:

• Anthropic
• OpenAI Foundation
• Flu Lab
• Bill Gates
• Traders from the quantitative investment firm Jane Street Capital

Nan Ransohoff, a Stripe executive, is leading the initiative alongside Charlie Petty, a venture capitalist who joined Stripe this year. The advisory board includes Peter Marks, a former FDA official, and Moncef Slaoui, who led Operation Warp Speed during the COVID-19 pandemic.

Intercept plans to deploy capital through grants and investments in two primary areas:

• Vaccines: funding next-generation vaccine development targeting a broad range of respiratory pathogens
• Air cleaning: deploying large-scale air filtration and treatment systems for schools, offices, hospitals, and public spaces to reduce transmission at the infrastructure level

The initiative was developed with input from David Veesler, a structural biologist at the University of Washington who has demonstrated that broad countermeasures effective against multiple virus types simultaneously are technically achievable.

Context

Respiratory infections — including the common cold, influenza, RSV, and COVID-19 — account for a substantial portion of global illness, missed work, and healthcare utilization, yet they attract limited preventive investment relative to their societal cost. Individual viruses are often considered manageable nuisances, and vaccine economics for pathogens like rhinovirus have historically discouraged development.

Intercept's founding reflects a growing belief among technology philanthropists that respiratory disease is a tractable, systems-level problem if attacked through both biology (broad-spectrum vaccines) and environment (engineered air). Stripe CEO Patrick Collison has previously backed pandemic preparedness through Fast Grants during COVID-19.

The participation of Anthropic and the OpenAI Foundation signals that AI companies are expanding into large-scale health philanthropy as a distinct commitment from their core model development work. AI tools — including protein-structure models and biological reasoning systems — are increasingly applied in vaccine design, and the involvement of AI labs may accelerate research pipelines Intercept funds.

Why it matters

At $500 million in founding capital, Intercept is one of the largest single philanthropic commitments to respiratory disease prevention. The fund's ambition — eliminating entire classes of viruses rather than treating individual outbreaks — is a departure from the reactive model that has governed pandemic and respiratory disease response for decades.

For the AI industry, the dual backing from Anthropic and the OpenAI Foundation marks a notable moment: two competing frontier AI labs publicly aligning on a health initiative alongside Stripe. It reinforces a pattern of AI-company capital flowing toward science and infrastructure problems that benefit from long time horizons and are unlikely to attract near-term commercial returns.

Whether the approach of combining vaccines and large-scale air cleaning can measurably reduce respiratory disease burden will take years to determine. But the scale of the initial commitment, and the caliber of the advisors and scientific collaborators involved, puts Intercept in a position to move faster than most public health programs could.